# Acesion Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acesion-pharma-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.acesionpharma.com
- Total disclosed funding: $48M
- Latest round: Series B (Sep 26, 2023)
- Investors on record: 4

## About

Based in Denmark, Acesion Pharma ApS develops innovative therapies for atrial fibrillation, addressing critical medical needs with its novel treatment approach.Founded in 2011, Acesion Pharma ApS is engaged in the development of therapies targeting atrial fibrillation (AF). The company is headquartered in Copenhagen, Denmark. Co-founded by Morten Grunnet and Ulrik Sørensen, Acesion has secured a total of EUR 45.00 mn in funding, with its most recent deal being a Series B round completed on September 26, 2023, involving investors such as Alpha Wave Global, Canaan Partners, Global BioAccess Fund, and Novo Holdings. The total amount raised is EUR 45.00 mn.Acesion Pharma ApS focuses on developing treatments for atrial fibrillation (AF), particularly through its lead compound AP30663, which targets the SK ion channel. This first-in-class drug aims to provide a novel mechanism for addressing AF, a condition affecting millions globally. The company actively works towards advancing therapies that can enhance patient outcomes in both the EU and US markets, catering to healthcare providers and patients suffering from AF.Acesion Pharma ApS reported zero revenue for the year 2021. The company's EBITDA for 2023 was -EUR 7,695,289.90. Revenue generation is structured around partnerships and collaborations in the biotechnology sector, focusing on their flagship product AP30663, and may involve B2B transactions with healthcare institutions.In September 2023, Acesion Pharma ApS raised EUR 45 million in Series B funding, co-led by Alpha Wave Global and Canaan Partners, alongside participation from Global BioAccess Fund and returning investor Novo Holdings. The funding will support the ongoing clinical development of AP31969, an SK ion channel inhibitor designed for chronic oral treatment of atrial fibrillation, indicating Acesion's commitment to expanding its product pipeline and advancing its therapeutic offerings into new markets.

## Funding rounds

- Series B, Sep 26, 2023, $48M — Canaan Partners, Novo Holdings, Alpha Wave Global, Global BioAccess Fund

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B
- Novo Holdings — Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series B
- Global BioAccess Fund (https://capitalatlas.ai/funds/global-bioaccess-fund) — Series B